Table 2 Baseline clinical characteristics and associated mortality and opportunistic infections of HIV-infected patients in Jimma University Specialized Hospital, between January 2006 and December 2011
Characteristics | Number of patients (%) | Number of deaths (%) | Number of OI (%) |
|---|---|---|---|
WHO clinical stage | |||
Stage I | 65 (19.1) | 6 (14.3) | 15 (18.1) |
Stage II | 95 (27.9) | 9 (21.4) | 15 (18.1) |
Stage III | 144 (42.4) | 17 (40.5) | 44 (53.0) |
Stage IV | 36 (10.6) | 10 (23.8) | 9 (10.8) |
HAART regimen | |||
Stavudine based | 219 (64.4) | 19 (45.2) | 60 (72.3) |
Zidovudine based | 72 (21.2) | 12 (28.6) | 18 (21.7) |
Tenofovir based | 49 (14.4) | 11 (26.2) | 5 (6.0) |
Base line CD4 | |||
>350 | 5 (1.5) | 0 (0.0) | 2 (2.4) |
200–350 | 94 (27.6) | 7 (16.7) | 19 (22.9) |
100–199 | 139 (40.9) | 15 (35.7) | 37 (44.6) |
<100 | 102 (30.0) | 20 (47.6) | 25 (30.1) |
Risky behaviour | |||
Yes | 120 (35.3) | 14 (33.3) | 58 (69.9) |
No | 220 (64.7) | 28 (67.7) | 25 (30.1) |
Cotrimoxazole prophylaxis | |||
Yes | 330 (97.1) | 42 (100.0) | 81 (97.6) |
No | 10 (2.9) | 0 (0.0) | 2 (2.4) |
Fluconazole prophylaxis | |||
Yes | 20 (5.9) | 8 (19.1) | 5 (6.0) |
No | 320 (94.1) | 34 (80.9) | 78 (94.0) |
INH prophylaxis | |||
Yes | 62 (18.2) | 7 (16.7) | 20 (24.1) |
No | 278 (81.8) | 35 (83.3) | 63 (75.9) |